Oppenheimer upgraded Dyne Therapeutics (DYN) to Outperform from Perform with a $40 price target
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics 18.98M share Secondary priced at $18.44
- Midday Fly By: Nvidia can ship H200s to China, Campbell’s reports Q1 beat
- Dyne Therapeutics falls -13.7%
- Dyne Therapeutics price target raised to $50 from $46 at Morgan Stanley
- Dyne Therapeutics price target raised to $23 from $21 at Bernstein